Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-007171
Filing Date
2025-05-09
Accepted
2025-05-09 16:05:33
Documents
51
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q sngx-20250331x10q.htm   iXBRL 10-Q 1316200
2 EX-10.1 sngx-20250331xex10d1.htm EX-10.1 19869
3 EX-31.1 sngx-20250331xex31d1.htm EX-31.1 18342
4 EX-31.2 sngx-20250331xex31d2.htm EX-31.2 19676
5 EX-32.1 sngx-20250331xex32d1.htm EX-32.1 8186
6 EX-32.2 sngx-20250331xex32d2.htm EX-32.2 11064
  Complete submission text file 0001558370-25-007171.txt   5526596

Data Files

Seq Description Document Type Size
7 EX-101.SCH sngx-20250331.xsd EX-101.SCH 28947
8 EX-101.CAL sngx-20250331_cal.xml EX-101.CAL 35336
9 EX-101.DEF sngx-20250331_def.xml EX-101.DEF 147760
10 EX-101.LAB sngx-20250331_lab.xml EX-101.LAB 300832
11 EX-101.PRE sngx-20250331_pre.xml EX-101.PRE 234846
54 EXTRACTED XBRL INSTANCE DOCUMENT sngx-20250331x10q_htm.xml XML 913384
Mailing Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540
Business Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540 609-538-8200
SOLIGENIX, INC. (Filer) CIK: 0000812796 (see all company filings)

EIN.: 411505029 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-14778 | Film No.: 25930339
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)